Literature DB >> 26561341

CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells.

Emanuele Trella1, Nermin Raafat1,2, Chantal Mengus1, Emmanuel Traunecker3, Valeria Governa1, Swantje Heidtmann4, Michael Heberer1, Daniel Oertli5, Giulio C Spagnoli1, Paul Zajac1.   

Abstract

Central memory CD8(+) T cells (TCM ) play key roles in the protective immunity against infectious agents, cancer immunotherapy, and adoptive treatments of malignant and viral diseases. CD8(+) TCM cells are characterized by specific phenotypes, homing, and proliferative capacities. However, CD8(+) TCM -cell generation is challenging, and usually requires CD4(+) CD40L(+) T-cell "help" during the priming of naïve CD8(+) T cells. We have generated a replication incompetent CD40 ligand-expressing recombinant vaccinia virus (rVV40L) to promote the differentiation of human naïve CD8(+) T cells into TCM specific for viral and tumor-associated antigens. Soluble CD40 ligand recombinant protein (sCD40L), and vaccinia virus wild-type (VV WT), alone or in combination, were used as controls. Here, we show that, in the absence of CD4(+) T cells, a single "in vitro" stimulation of naïve CD8(+) T cells by rVV40L-infected nonprofessional CD14(+) antigen presenting cells promotes the rapid generation of viral or tumor associated antigen-specific CD8(+) T cells displaying TCM phenotypic and functional properties. These observations demonstrate the high ability of rVV40L to fine tune CD8(+) mediated immune responses, and strongly support the use of similar reagents for clinical immunization and adoptive immunotherapy purposes.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antigen presenting cells; CD4+ T cells; CD40-CD40L; CD8+ T cells; Central memory T cells; Immunological memory; Vaccinia virus

Mesh:

Substances:

Year:  2015        PMID: 26561341     DOI: 10.1002/eji.201545554

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

Authors:  Dev Karan
Journal:  Vaccine       Date:  2017-09-20       Impact factor: 3.641

2.  Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection.

Authors:  Sarah M Engle; Ching-Yun Chang; Benjamin J Ulrich; Allyson Satterwhite; Tristan Hayes; Kim Robling; Sean E Sissons; Jochen Schmitz; Robert S Tepper; Mark H Kaplan; Jonathan T Sims
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

3.  Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection.

Authors:  Sarah M Engle; Ching-Yun Chang; Benjamin J Ulrich; Allyson Satterwhite; Tristan Hayes; Kim Robling; Sean E Sissons; Jochen Schmitz; Robert S Tepper; Mark H Kaplan; Jonathan T Sims
Journal:  Clin Exp Immunol       Date:  2021-11-30       Impact factor: 5.732

4.  A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo.

Authors:  Valeria Governa; Alvaro Brittoli; Valentina Mele; Maurizio Pinamonti; Luigi Terracciano; Simone Muenst; Giandomenica Iezzi; Giulio Cesare Spagnoli; Paul Zajac; Emanuele Trella
Journal:  Oncoimmunology       Date:  2019-02-14       Impact factor: 8.110

5.  CD40 Accelerates the Antigen-Specific Stem-Like Memory CD8+ T Cells Formation and Human Papilloma Virus (HPV)-Positive Tumor Eradication.

Authors:  Yanmei Zhang; Nisha Wang; Meilin Ding; Yang Yang; Zhimin Wang; Lei Huang; Wei Zhu; Andrew L Mellor; Xiaorui Hou; Chenfei Zhou; Ruiming Yan; Wei Wang; Sha Wu
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.